Navigation Links
VIA Pharmaceuticals Set to Join Russell Microcap Index
Date:6/27/2008

Russell serves individual, institutional and advisor clients in more than 40 countries. Russell provides access to some of the world's best money managers. It helps investors put this access to work in corporate defined benefit and defined contribution plans, and in the life savings of individual investors.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The company's lead drug candidate, VIA-2291, is in multiple Phase 2 clinical studies in patients with cardiovascular disease. For more information, visit: http://www.viapharmaceuticals.com.

Forward-Looking Statements

This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or to VIA's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause VIA's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in s
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Wyeth Pharmaceuticals Announces Organizational Change
2. Access Pharmaceuticals Presents New Data at International Symposium Showing Companys Angiolix(R) Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells
3. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
4. Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
5. Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development
6. Brian Levy, OD, MSc, Named Chief Operating Officer of Danube Pharmaceuticals
7. Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
8. Onyx Pharmaceuticals to Present at Jefferies 2nd Annual Healthcare Conference
9. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
10. Immtech Pharmaceuticals and Beijing Capital Medical University Announce Joint Venture to Provide Contract Research Services in China
11. Synovics Pharmaceuticals Announces Continued Growth of Customer Relationships
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... Texas (PRWEB) , ... July 03, 2015 , ... ... firm, highly-regarded by Fortune 500 companies and professional service industries alike-- typically known ... to make clients laugh, honor a good cause and break from their day ...
(Date:7/3/2015)... Forskere kan ansøge ... http://www.openinnovationinscience.at om efteruddannelsesprogrammet "Lab for Open ... Wien .  ... og videnskabsmænd foretaget af Ludwig Boltzmann Gesellschaft ... sundhedsvidenskaben manglen på incitamenter til at undersøge ...
(Date:7/2/2015)... , ... July 02, 2015 , ... Sleepless nights will ... individual’s quality of sleep, launched its Indiegogo campaign on June 23. Sound sleepers and ... command technology makes it effortless to use, while the integration of the Bluetooth speaker, ...
(Date:7/1/2015)... ... 2015 , ... The next-generation sequencing (NGS) clinical market is poised for huge ... industry. BCC Research reveals in its new report that the market drivers of this ... growing need for better diagnostics as part of a molecular diagnostics trend. , The ...
Breaking Biology Technology:The Alexander Group Declares Their Independence with a Bit of Levity 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 3Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3
... - Strengthened Balance Sheet and Advancing Products in 2008 - ... 11:00 a.m. Eastern Time -, BRANFORD, Conn., Jan. 31 ... financial results for the,fourth quarter and fiscal year ended December ... the fourth quarter of 2007,of $11.0 million, or $0.20 per ...
... (Euronext: AMT), a leader in the field of ... plan of rotation to appoint independent,directors to its ... Mr. Philippe van Holle, Head of Celgene Europe ... of shareholders. Mr. Van Holle is expected to,replace ...
... FRANCISCO, Calif., Jan. 30 Monogram,Biosciences, Inc., (Nasdaq: ... on Thursday, February 7, 2008 at 4:30 p.m. (Eastern ... discuss the outlook for 2008.,The call will be hosted ... To participate in the live teleconference, please call ...
Cached Biology Technology:CuraGen Reports Fourth Quarter and Year End 2007 Financial Results 2CuraGen Reports Fourth Quarter and Year End 2007 Financial Results 3CuraGen Reports Fourth Quarter and Year End 2007 Financial Results 4CuraGen Reports Fourth Quarter and Year End 2007 Financial Results 5CuraGen Reports Fourth Quarter and Year End 2007 Financial Results 6CuraGen Reports Fourth Quarter and Year End 2007 Financial Results 7Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board 2Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board 3Monogram Biosciences Announces Fourth Quarter 2007 Financial Results Conference Call 2
(Date:6/23/2015)... , June 23, 2015  Crossmatch™, a ... authentication solutions, today announced enhanced functionality of its ... solution.  The enhancements build on the native ... DigitalPersona Altus platform and provide expanded mobile ... In today,s environment of increasing cyber-attacks ...
(Date:6/17/2015)... Maryland , and HILDEN, Germany , ... QGEN ; Frankfurt Prime Standard: QIA) today launched new ... evidence in forensic laboratories in the United States ... solution to simultaneously analyze multiple key genomic markers (short tandem ... ® Quality Sensor to evaluate the quality of DNA ...
(Date:6/16/2015)... , June 16, 2015  With the increasing ... security remains a top concern. The recent compromise of ... the need for strong authentication within government agencies. ... a biometric one-time password (OTP) authenticator, has been submitted ... (FIPS) 140-2 Level 3 validation for tamper proofing. ...
Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
... developed a method to dramatically improve the longevity of ... motion of a single molecule as it travels through ... process called resonance energy transfer, which occurs when fluorescent ... will be reported at the 234th annual national American ...
... Staph Infections in Humans Including MRSA ... against Staphylococcus aureus, including methicillin-resistant strains, in mice ... in the August 2007 issue of the journal ... a highly flexible and potentially dangerous pathogen capable ...
... study in the August 21st issue of Current Biology, a ... evidence in support of the long-held notion that men and ... the researchers found that women really do prefer pinkor at ... we expected to find sex differences, we were surprised at ...
Cached Biology News:Clemson scientists shed light on molecules in living cells 2Tips from the Journals of the American Society for Microbiology 2Tips from the Journals of the American Society for Microbiology 3Girls prefer pink, or at least a redder shade of blue 2